1 / 12

ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT

ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT. J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California Calabasas, California October 14, 2004 Slides at: www.medafile.com (Dr. Ashford’s lectures).

ossie
Download Presentation

ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ALZHEIMER’S DISEASEDIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California Calabasas, California October 14, 2004 Slides at: www.medafile.com (Dr. Ashford’s lectures)

  2. Diagnostic Criteria For Dementia Of The Alzheimer Type(DSM-IV, APA, 1994) • Multiple Cognitive Deficits 1. Memory Impairment 2. Other Cognitive Impairment B. Deficits Impair Social/Occupational • Course Shows Gradual Onset And Decline • Deficits Are Not Due to: 1. Other CNS Conditions 2. Substance Induced Conditions E. Do Not Occur Exclusively during Delirium F. Not Due to Another Psychiatric Disorder

  3. PREVALENCE of AD • Estimated 4 million cases in US (2000) • (2000 - 46 million individuals over 60 y/o) • Estimated 500,000 new cases per year • Increase with age (prevalence) • 1% of 60 - 65 (10.7m) = 107,000 • 2% of 65 - 70 ( 9.4m) = 188,000 • 4% of 70 - 75 ( 8.7m) = 350,000 • 8% of 75 - 80 ( 7.4m) = 595,000 • 16% of 80 - 85 ( 5.0m) = 800,000

  4. Assessment History Of The Development Of The Dementia • Ask the Patient What Problem Has Brought Him to See You • Ask the Family, Companion about the Problem • Specifically Ask about Memory Problems • Ask about the First Symptoms • Enquire about Time of Onset • Ask about Any Unusual Events Around the Time of Onset, e.g., stress, trauma, surgery • Ask about Nature and Rate of Progression, Activities of Daily Living • Physical Examination • Neurological Examination • Neuropsychological Assessment • Routine Laboratory Tests • Brain Scan

  5. Why Diagnose AD Early? • Safety (driving, compliance, cooking, etc.) • Family stress and misunderstanding (blame, denial) • Early education of caregivers of how to handle patient (choices, getting started) • Advance planning while patient is competent (will, proxy, power of attorney, advance directives) • Patient’s and Family’s right to know • Promotes advocacy for research and treatment development • Specific treatments now available • May slow underlying disease process, the sooner the better • May delay nursing home placement longer if started earlier • May prevent conversion from Mild Cognitive Impairment to AD

  6. Dementia Screening Test • Need to get elderly, clinicians interested in screening for dementia • Need test to screen patients for Alzheimer’s disease • Test needs to be on multiple platforms: • Doctor’s offices • Best if computerized for rapid, objective assessment • World-Wide Web – based testing, • CD-distribution • KIOSK administration – drug stores, shopping malls • Test needs to be very brief (about 1-minute) • Multiple test forms needed so it can be repeated often (quarterly) • Screening should be done yearly after age 50, and repeated every 3 months for individuals over 65 years of age or with concerns • Any change over time needs to be detected • The test should be free • Need program to handle positive screens sensitively and efficiently • Doctors have been reluctant to diagnose Alzheimer’s disease because of the time required to explain the problem to the family and to coordinate treatment.

  7. MEMTRAX - Memory Test(to detect AD onset) • New test to screen patients for AD: • World-Wide Web – based testing, • CD-distribution • KIOSK administration • Determine level of ability / impairment • Test takes about 1-minute • Test can be repeated often (e.g., quarterly) • Any change over time can be detected • Free test is at: www.medafile.com

  8. FIRST SUCCESSFUL TREATMENT: • CHOLINESTERASE INHIBITION • (1st double blind study - Ashford et al., 1981) • Presumably increases acetylcholine at synapses • Improvement in cognition (? 6-12 months better) • Improvement in function (ADLs, variable) • Improvement in behavior (stabilization? basal ganglia) • Slowing of disease course • Treatment delays nursing home placement • Loss of benefit with delay of treatment • Need to consider early intervention • Prevent conversion from Mild Cognitive Impairment to AD

  9. Need to divide effects of drug treatment into 2 groups • Acute effects of treatment • e.g., 3 months • are the acute effects related to severity? • e.g., do AChEases may work very well in mild patients, and in nursing home patients? • do these medications work in very early phases of the disease? • Chronic effects of treatment • rate of change, after acute effects • are the effects on rate of change related to severity • are very mild patients improved over time by AChEases? • are new AChEase molecules created which require dose increases? • does sudden discontinuation lead to catastrophic decline? • do early, chronic benefits suggest prevention?

  10. Benefits of Treatment of AD With Acetylcholinesterase Inhibitors • AChEIs may improve, maintain, or slow the decline of cognitive, behavioral, and functional performance in patients with mild-to-moderate AD • Delay of treatment leads to loss of potential benefit • AChEIs may delay nursing home placement over 20 months, and potentially much more when started early. • AChEIs have demonstrated consistent efficacy and safety in maintaining cognitive function, as measured by ADAS-cog in patients with mild-to-moderate AD for up to 1 year – relative to placebo!! • Donepezil1 38 weeks • Rivastigmine2 38–42 weeks • Galantamine3 52 weeks (25-30% better) 1. Rogers SL et al. Eur Neuropsychopharmacol. 2000;10:195-203. 2. Farlow M et al. Eur Neurol. 2000;44:236-241. 3. Raskind MA et al. Neurology. 2000;54:2261-2268.

  11. Reminyl®(galantamine HBr): Proposed Mechanisms of Action • Increases amount of acetylcholine available in synaptic cleft by inhibiting breakdown of acetylcholine • By modulating activity at nicotinic receptors, it may increase release of acetylcholine from surviving presynaptic nerve terminals • Combination action may diminish cholinesterase supersensitivity from developing, prolonging the benefit. • May provide greatest delay of illness progression • May require increase of dose after patient declines below initial baseline, to maintain benefit for longer term. Maelicke A, Albuquerque EX. Eur J Pharmacol. 2000;393:165-170.

  12. Reminyl® (galantamine HBr): Dosing • Available in 4-mg, 8-mg, and 12-mg tablets and oral solution (4 mg/mL) • Dose escalation • 8 mg/day starting dose • for 4 weeks (4 mg bid) • 16 mg/day maintenance dose • for at least 4 weeks (8 mg bid) • The flexibility to increase to 24 mg/day • (12 mg bid) – can try after 12 weeks if further benefit sought • Increase from 8 to 12 mg bid in moderate dementia • Take initially with morning and evening meals • Later, better with morning meal, mid-afternoon snack. • (Avoid nocturnal cholinergic activation which may hasten the progression of Alzheimer’s disease!! – advantage over donepezil)

More Related